Clinical trials: Resectable NSCLC
- Condition Resectable NSCLC
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Non-Small Cell Lung Cancer - Completely Resectable
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
- Trial name
- NCT00298298
- Testing
- L-Vax: Autologous, DNP-Modified NSCLC Vaccine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- AVAX Technologies